Results 141 to 150 of about 58,665 (272)

Conclusion lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™: chronic obstructive pulmonary disease and drug development implications

, 2003
P. M. A. Calverley, E.T. Keating, Mitch Goldman, Frank E. Casty   +3 more
openalex   +1 more source

Dopamine D1 Receptor Agonist and D2 Receptor Antagonist Effects of the Natural Product (−)–Stepholidine: Molecular Modeling and Dynamics Simulations [PDF]

, 2007
Wei Fu, Jianhua Shen, Xiaomin Luo, Weiliang Zhu, Jiagao Cheng, Kunqian Yu, James M. Briggs, Guo-Zhang Jin, Kaixian Chen, Hualiang Jiang   +9 more
openalex   +1 more source

(±)VK4‐40, a novel dopamine D₃ receptor partial agonist, attenuates cocaine reward and relapse in rodents [PDF]

, 2020
Chloe J. Jordan, Yi He, Guo‐Hua Bi, Zhi‐Bing You, Jianjing Cao, Zheng‐Xiong Xi, Amy Hauck Newman   +6 more
openalex   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Othello Syndrome Induced by Dopamine Agonists in Parkinson's Disease: A Case Report. [PDF]

Case Rep Psychiatry
Ahmed GU, Ahmed HU, Raza AA, Samadi A.
europepmc   +1 more source

Quantitative Evaluation of Pupil Responses in Patients with Prolactinomas Being Treated with Dopamine Agonists. [PDF]

Neuroophthalmology, 2022
Ava S, Hazar L, Karahan M, Erdem S, Dursun ME, Pekkolay Z, Keklikçi U.   +6 more
europepmc   +1 more source

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin) [PDF]

, 2013
Deanna L. Kelly, Heidi J. Wehring, Amber Earl, Kelli M. Sullivan, Faith Dickerson, Stephanie Feldman, Robert P. McMahon, Robert W. Buchanan, Dale Warfel, William R. Keller, Bernard A. Fischer, Joo-Cheol Shim   +11 more
openalex   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein. [PDF]

Bioorg Med Chem, 2023
Dinda B, Das B, Biswas S, Sharma H, Armstrong C, Yedlapudi D, Antonio T, Reith M, Dutta AK.   +8 more
europepmc   +1 more source

Dopamine Agonist [PDF]

, 2020
openaire   +1 more source